Importance Additional treatments are needed for heart failure with reduced ejection fraction
(HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment …

Background: Patients with heart failure (HF) and reduced ejection fraction will experience
multiple hospitalizations for heart failure during the course of their disease. We assessed the …

Background: The DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure) showed that dapagliflozin added to other guideline-recommended therapies …

Background A pre-specified meta-analysis of cardiovascular (CV) events from 21 phase
2b/3 dapagliflozin clinical trials was undertaken to characterise the CV profile of …

Background SGLT2 inhibition decreases albuminuria and reduces the risk of kidney disease
progression in patients with type 2 diabetes. These benefits are unlikely to be mediated by …

People with diabetes are more likely to develop a cardiovascular (CV) disease compared
with those without diabetes. Although effective glycemic control has been the focus of the …

Aims Blood uric acid (UA) levels are frequently elevated in patients with heart failure and
reduced ejection fraction (HFrEF), may lead to gout and are associated with worse …

OBJECTIVE To assess the efficacy and safety of dapagliflozin, a selective sodium-glucose
cotransporter 2 inhibitor, compared with placebo in patients with type 2 diabetes (T2D) …

Importance In 2 trials enrolling patients with heart failure (HF) across the spectrum of
ejection fraction (EF), dapagliflozin has been shown to reduce the rate of the composite of …

Objective To determine the impact of sodium-dependent glucose type 2 cotransporter
inhibitors on the renal function in acute heart failure. Methods In a single-centre, controlled …